Suppr超能文献

酒精戒断综合征的新兴治疗选择。

Emerging treatment options in the alcohol withdrawal syndrome.

作者信息

Rosenbloom A

机构信息

Division of Critical Care Medicine, Presbyterian University Hospital, Pittsburgh, PA 15213.

出版信息

J Clin Psychiatry. 1988 Dec;49 Suppl:28-32.

PMID:2904429
Abstract

Severe alcohol withdrawal has a mortality rate of 5% to 10%. Uncontrolled bouts may sensitize the patient, making future episodes more frequent and severe. Thus, aggressive treatment that produces rapid control of alcohol withdrawal is essential. The author briefly discusses some of the neuropharmacological aspects of alcohol's actions and alcohol withdrawal. Drug treatment options are also considered. Benzodiazepines offer the highest margin of safety. Lorazepam is an excellent first choice because of its intermediate half-life, absence of active metabolites, and high bioavailability that can be achieved with a number of routes of administration. Combination therapy with clonidine, beta-adrenergic blocking agents, and haloperidol is becoming increasingly attractive because it results in decreased sedation, better control of delirium, less respiratory depression, and improved outcome. The availability of shorter half-life, rapid-acting drugs like esmolol and midazolam, administered by continuous infusion, makes dose titration more precise in the critically ill patient.

摘要

严重酒精戒断的死亡率为5%至10%。未得到控制的发作可能会使患者产生敏感性,导致未来发作更加频繁和严重。因此,迅速控制酒精戒断的积极治疗至关重要。作者简要讨论了酒精作用及酒精戒断的一些神经药理学方面。还考虑了药物治疗选择。苯二氮䓬类药物安全性最高。劳拉西泮是极佳的首选药物,因其半衰期适中、无活性代谢产物且可通过多种给药途径实现高生物利用度。可乐定、β-肾上腺素能阻滞剂和氟哌啶醇联合治疗越来越具有吸引力,因为它能减少镇静作用、更好地控制谵妄、减轻呼吸抑制并改善预后。半衰期较短、起效迅速的药物如艾司洛尔和咪达唑仑可通过持续输注给药,这使得在重症患者中剂量滴定更加精确。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验